Generation Bio

Generation Bio EBITDA per Employee

Delisted

The EBITDA per Employee of Generation Bio (GBIO) as of Nov 10, 2026 is -1.24 M USD. In the previous year, EBITDA per Employee was -1.20 M USD — a change of 2.76% (lower).

EBITDA per Employee

-1.24 MUSD

YoY

2.76%

Last updated:

EBITDA per Employee of Generation Bio is 2024 -1.24 M USD. EBITDA per Employee of Generation Bio was 2023 -1.20 M USD. It decreases by 2.76% lower compared to the previous year.

The Generation Bio EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-324,295.65 USD
Jan 1, 2019
-541,756.52 USD
Jan 1, 2020
-705,339.13 USD
Jan 1, 2021
-1.04 M USD
Jan 1, 2022
-1.23 M USD
Jan 1, 2023
-1.20 M USD
Jan 1, 2024
-1.24 M USD
The Generation Bio EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.24 MUSD+2.76%
-1.20 MUSD-1.86%
-1.23 MUSD+18.54%
-1.04 MUSD+46.83%
-705,339.13USD+30.19%
-541,756.52USD+67.06%
-324,295.65USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

EBITDA per Employee of Generation Bio is -1.24 M USD in 2024.

EBITDA per Employee of Generation Bio changed from -1.20 M USD to -1.24 M USD, representing a 2.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Generation Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Generation Bio

All Key Metrics — Generation Bio